

Special Issue

Burkitt Lymphoma: From Pathogenesis to Current Treatments

Message from the Guest Editors

The aim of this Special Issue will be to investigate the pathogenesis of Burkitt Lymphoma (BL) in depth, in relation to possible new therapeutic approaches. There are still many questions that need to be addressed regarding the differences between EBV-positive and EBV-negative BL, which may originate from cells at different steps of B-cell differentiation, different mechanisms of activation of BCR signaling, and *MYC* translocation. These goals can be achieved via the application of innovative molecular analyses such as whole-exome sequencing, RNA sequencing, methylation analysis, targeted NGS analysis, and proteomics, to name a few. The application of some of these techniques to routine practice could also improve the diagnosis of BL. One other issue would be to better define the distribution of EBV-positive cases in relation to age, geographical distribution, and possible associations with other infectious agents, following new evidence that the epidemiology of BL is changing in endemic areas. Original research articles and reviews are welcome. We look forward to receiving insightful contributions. and

Guest Editors

Prof. Dr. Lorenzo Leoncini

Department of Medical Biotechnology, University of Siena, Siena, Italy

Prof. Dr. German K. Ott

Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany

Deadline for manuscript submissions

30 September 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/211905

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)